# US 2026/0097076 A1 · Chimeric antigen receptors specific to b-cell mature antigen (bcma) and/or transmembrane activator and caml interactor (taci)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097076 A1
- Document ID: US20260097076A1
- Status: Published application
- Kind: A1
- Application number: 19/112,720
- Filed: 2023-09-20
- Published: 2026-04-09
- Earliest claimed: 2022-09-21
- Assignees: Elpis Biopharmaceuticals
- Applicants: Elpis Biopharmaceuticals
- Inventors: Yan CHEN; Garima AGRAHARI; Kehao ZHAO; Jenna NGUYEN; Keming ZHANG; Ning JIANG; Katie O'CALLAGHAN
- Web page: https://patentgrep.com/patent/US20260097076A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C12N 15/86: Viral vectors
- A61K 2239/10: characterized by the structure of the chimeric antigen receptor [CAR]
- A61K 2239/13: Antibody-based
- A61K 2239/17: Hinge-spacer domain
- A61K 2239/21: Transmembrane domain
- A61K 2239/29: Multispecific CARs
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C12N 2740/15041: Use of virus, viral particle or viral elements as a vector
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Genetically engineered immune cells (e.g., T cells or NK cells) expressing anti-BCMA, anti-TACI, or anti-BCMA/anti-TACI chimeric antigen receptors and uses thereof in cancer therapy. In some embodiments, the genetically engineered immune cells may be armored CAR-T or CAR-NK cells, which further express an armor polypeptide for enhancing CAR-T or CAR-NK cell features.

## Claims

### Claim 1

A bi-specific chimeric antigen receptor (CAR) specific to B-cell mature antigen (BCMA) and transmembrane activator and CAML interactor (TACI), the bi-specific CAR comprising:
(a) a first antigen binding moiety specific to TACI;
(b) a second antigen binding moiety specific to BCMA;
(c) a co-stimulatory signaling domain; and
(d) a cytoplasmic signaling domain.

### Claim 2 (depends on 1)

The bi-specific CAR of claim 1, wherein the first antigen binding moiety specific to TACI of (a) comprises a heavy chain variable region (VH) and a light chain variable region (VL); wherein the VH comprise the same heavy chain CDRs as those in a reference antibody, and the VL comprise the same heavy chain CDRs as those in the reference antibody; and wherein the reference antibody is TC-01, TC-02, TC-03, or TC-04; optionally wherein the reference antibody is TC-01.

### Claim 3 (depends on 2)

The bi-specific CAR of claim 2, wherein the VH and VL of the first antigen binding moiety specific to TACI are identical to the VH and VL of the reference antibody.

### Claim 4 (depends on 1)

The bi-specific CAR of claim 1, wherein the first antigen binding moiety specific to TACI is a single chain variable fragment (anti-TACI scFv).

### Claim 5 (depends on 4)

The bi-specific CAR of claim 4, wherein the anti-TACI scFv comprises an amino acid sequence of any one of SEQ ID NOs: 75, 84, 93, and 102; optionally wherein the anti-TACI scFv comprises the amino acid sequence of SEQ ID NO: 75.

### Claim 6 (depends on 1)

The bi-specific CAR of claim 1, wherein the second antigen binding moiety specific to BCMA of (a) comprises a heavy chain variable region (VH) and a light chain variable region (VL);
wherein the VH comprises:
(hi) a heavy chain complementarity determining region (CDR) 1, which comprises X1YX2MH, in which X1 is S or D, and X2 is A or G;
(hii) a heavy chain CDR2, which comprises
(hii-a) X3IX4YDGSX5KYYADSVKG (SEQ ID NO: 1), in which X3 is V or F, X4 is S or R, and X5 is D or N;
(hii-b)
(SEQ ID NO: 27)
FIRSKAYGGTTEYAASVKG;
or
(hii-c)
(SEQ ID NO: 43)
GISWNSGSIGYADSVKG;
and
(hiii)
a heavy chain CDR3, which comprises
(hiii-a)
(SEQ ID NO: 56)
DEHQVVPNYRFDF,
(hiii-b)
(SEQ ID NO: 35)
DWEDPLYYYDTPF,
(hiii-c)
(SEQ ID NO: 16)
DWDYYDSSGYYPDALGI,
(hiii-d)
(SEQ ID NO: 9)
DLWDGIVGAPAGY,
(hiii-e)
(SEQ ID NO: 22)
DLTTITPGY,
(hiii-f)
(SEQ ID NO: 63)
DLWEFGGDYADY,
(hiii-g)
(SEQ ID NO: 28)
GPHYDILTSNWFDP,
or
(hiii-h) VQX6PGAFDI (SEQ ID NO: 181), in which X6 is P or S; and
wherein the VL comprises:
(li) a light chain CDR1, which comprises
(li-a) SGSGSNIGSNDVS (SEQ ID NO: 58),
(li-b) QASQDIX7NYLN (SEQ ID NO: 2), in which X7 is N or S, or
(li-c) RX8X9X10ISSYLX11 (SEQ ID NO: 3), in which X8 is A or S, X9 is S or T, X10 is G or S, and X11 is G or N;
(lii) a light chain CDR2, which comprises
(lii-a) WNDQRPS (SEQ ID NO: 59),
(lii-b) DASNX12ET (SEQ ID NO: 4), in which X12 is L or V, or
(lii-c) AX13SX14LQS (SEQ ID NO: 5), in which X13 is A or T, and X14 is S or T; and
(liii) a light chain CDR3, which comprises
(liii-a)
(SEQ ID NO: 60)
AAWDDSLNGWV,
(liii-b) QQYDX15LPX16T (SEQ ID NO: 6), in which X15 is K or N, and X16 is F, L, or Y,
(liii-c)
(SEQ ID NO: 32)
QHSYSTPHT,
or
(liii-d)
(SEQ ID NO: 48)
QQLYS.

### Claim 7 (depends on 6)

The bi-specific CAR of claim 6, wherein the VH of the second antigen binding moiety specific to BCMA comprise the same heavy chain CDRs as those in a reference antibody, and/or wherein the VL of the second antigen binding moiety specific to BCMA comprise the same heavy chain CDRs as those in the reference antibody; the reference antibody being BC-01, BC-02, BC-03, BC-04, BC-05, BC-06, BC-07, BC-08 or BC-09; optionally wherein the reference antibody is BC-06.

### Claim 8 (depends on 7)

The bi-specific CAR of claim 7, wherein the VH and VL of the second antigen binding moiety specific to BCMA are identical to the VH and VL of the reference antibody.

### Claim 9 (depends on 1)

The bi-specific CAR of claim 1, wherein the second antigen binding moiety specific to BCMA is a single chain variable fragment (anti-BCMA scFv).

### Claim 10 (depends on 9)

The bi-specific CAR of claim 9, wherein the anti-BCMA scFv comprises an amino acid sequence of any one of SEQ ID NOs: 15, 20, 25, 34, 41, 50, 53, 62, and 66; optionally wherein the anti-BCMA scFv comprises the amino acid sequence of SEQ ID NO:50.

### Claim 11 (depends on 1)

The bi-specific CAR of claim 1, wherein the co-stimulatory signaling domain is from a co-stimulatory molecule selected from the CD28, 4-1BB, OX40, ICOS, CD27, CD40, or CD40L.

### Claim 12 (depends on 11)

The bi-specific CAR of claim 11, wherein the cytoplasmic signaling domain is from CD3ζ.

### Claim 13 (depends on 1)

The bi-specific CAR of claim 1, wherein the bi-specific CAR comprises:
(a) a fusion polypeptide comprising, from N-terminus to C-terminus, (i) the first antigen binding moiety, (ii) the second antigen binding moiety, (iii) the co-stimulatory signaling domain, and (iv) the cytoplasmic signaling domain; or
(b) a fusion polypeptide comprising, from N-terminus to C-terminus, (i) the second antigen binding moiety, (ii) the first antigen binding moiety, (iii) the co-stimulatory signaling domain, and (iv) the cytoplasmic signaling domain.

### Claim 14 (depends on 13)

The bi-specific CAR of claim 13, further comprising a hinge domain and a transmembrane domain, which are located between (ii) and (iii).

### Claim 15 (depends on 13)

The bi-specific CAR of claim 13, further comprising a peptide linker connecting the first antigen binding moiety and the second antigen binding moiety.

### Claim 16 (depends on 15)

The bi-specific CAR of claim 15, wherein the peptide linker comprises the amino acid sequence of GGGGS (SEQ ID NO: 104), GGGGSGGGGS (SEQ ID NO: 105), GGGGSGGGGSGGGGS (SEQ ID NO: 106), or GSTSGSGKPGSGEGSTKG (SEQ ID NO: 107).

### Claim 17 (depends on 1)

The bi-specific CAR of claim 1, further comprising a signal peptide at the N-terminus.

### Claim 18 (depends on 1)

The bi-specific CAR of claim 1, which comprises the amino acid sequence of SEQ ID NO: 182.

### Claim 19 (depends on 18)

The bi-specific CAR of claim 18, which comprises the amino acid sequence of SEQ ID NO: 165 or 166.

### Claim 20 (depends on 1)

A nucleic acid or a set of nucleic acids, which collectively encode the bi-specific CAR of claim 1.

### Claim 21 (depends on 20)

The nucleic acid or set of nucleic acids of claim 20, wherein the nucleic acid comprises a first nucleotide sequence encoding the bi-specific CAR, which comprises:
(a) a fusion polypeptide comprising, from N-terminus to C-terminus, (i) the first antigen binding moiety, (ii) the second antigen binding moiety, (iii) the co-stimulatory signaling domain, and (iv) the cytoplasmic signaling domain; or
(b) a fusion polypeptide comprising, from N-terminus to C-terminus, (i) the second antigen binding moiety, (ii) the first antigen binding moiety, (iii) the co-stimulatory signaling domain, and (iv) the cytoplasmic signaling domain.

### Claim 22 (depends on 21)

The nucleic acid or set of nucleic acids of claim 21, wherein the nucleic acid further comprises a second nucleotide sequence encoding an armor polypeptide, which enhances T cell functionality, and a third nucleotide sequence encoding a self-cleaving peptide, which is located between the first and second nucleotide sequences.

### Claim 23 (depends on 22)

The nucleic acid or set of nucleic acids of claim 22, wherein the armor polypeptide is IL-2, IL-5, IL-15, a co-stimulatory ligand, an anti-PDL1 antibody, or a fusion polypeptide comprising the anti-PDL1 antibody; optionally wherein the anti-PDL1 antibody is a single chain variable fragment (scFv), which is fused to an IL-2 polypeptide.

### Claim 24 (depends on 23)

The nucleic acid or set of nucleic acid of claim 23, wherein the armor polypeptide comprises an amino acid sequence of SEQ ID NO: 168, 170, 172, 174, 178, or 180; optionally wherein the armor polypeptide comprises the amino acid sequence of SEQ ID NO: 178.

### Claim 25 (depends on 20)

The nucleic acid or set of nucleic acids of claim 20, wherein the nucleic acid(s) is an expression vector(s), optionally a viral vector(s).

### Claim 26 (depends on 1)

A genetically engineered immune cell, which expresses the bi-specific CAR of claim 1, and optionally further expresses an armor polypeptide, which enhances T cell functionality.

### Claim 27 (depends on 26)

The genetically engineered immune cell of claim 26, which expresses (a) the bispecific CAR comprising the amino acid sequence of SEQ ID NO: 165 or 166, and (b) the armor polypeptide comprising the amino acid sequence of SEQ ID NO: 177 or 178, or the armor polypeptide comprising the amino acid sequence of SEQ ID NO: 173 or 174.

### Claim 28 (depends on 26)

The genetically engineered immune cell of claim 26, which comprises the nucleic acid encoding the bi-specific CAR.

### Claim 29 (depends on 26)

The genetically engineered immune cell of claim 26, which is a T cell, an NK cell, or a macrophage, optionally wherein the immune cell is a T cell.

### Claim 30 (depends on 2)

An anti-TACI chimeric antigen receptor (CAR), comprising an extracellular antigen binding domain specific TACI, a co-stimulatory signaling domain, and a cytoplasmic signaling domain; wherein the extracellular antigen binding domain specific to TACI asset forth in claim 2.

### Claim 31 (depends on 30)

The anti-TACI CAR of claim 30, wherein the co-stimulatory signaling domain is from a co-stimulatory molecule selected from the CD28, 4-1BB, OX40, ICOS, CD27, CD40, or CD40L; and/or wherein the cytoplasmic signaling domain is from CD3ζ.

### Claim 32 (depends on 30)

The anti-TACI CAR of claim 30, further comprising a hinge domain and/or a transmembrane domain between the extracellular antigen binding domain specific to TACI and the co-stimulatory domain.

### Claim 33 (depends on 32)

The anti-TACI CAR of claim 32, which comprises both the hinge domain and the transmembrane domain, and wherein the anti-TACI CAR further comprises a spacer between the hinge domain and the transmembrane domain.

### Claim 34 (depends on 30)

The anti-TACI CAR of claim 30, which comprises an amino acid sequence of any one of SEQ ID NOs: 143-162; optionally wherein the anti-TACI CAR comprises the amino acid sequence of SEQ ID NO: 143 or 144.

### Claim 35 (depends on 6)

An anti-BCMA chimeric antigen receptor (CAR), comprising an extracellular antigen binding domain specific BCMA, a co-stimulatory signaling domain, and a cytoplasmic signaling domain; wherein the extracellular antigen binding domain specific to BCMA asset forth in claim 6.

### Claim 36 (depends on 35)

The anti-BCMA CAR of claim 35, wherein the co-stimulatory signaling domain is from a co-stimulatory molecule selected from the CD28, 4-1BB, OX40, ICOS, CD27, CD40, or CD40L; and/or wherein the cytoplasmic signaling domain is from CD3ζ.

### Claim 37 (depends on 35)

The anti-BCMA CAR of claim 35, further comprising a hinge domain and/or a transmembrane domain between the extracellular antigen binding domain specific to BCMA and the co-stimulatory domain.

### Claim 38 (depends on 37)

The anti-BCMA CAR of claim 37, which comprises both the hinge domain and the transmembrane domain, and wherein the anti-BCMA CAR further comprises a spacer between the hinge domain and the transmembrane domain.

### Claim 39 (depends on 35)

The anti-BCMA CAR of claim 35, which comprises an amino acid sequence of any one of SEQ ID NOs: 119-142; optionally wherein the anti-BCMA CAR comprises the amino acid sequence of SEQ ID NO: 127 or 128.

### Claim 40 (depends on 1)

A nucleic acid, comprising a first nucleotide sequence encoding an anti-TACI CAR or an anti-BCMA CAR of claim 1.

### Claim 41 (depends on 40)

The nucleic acid of claim 40, further comprising a second nucleotide sequence encoding an armor polypeptide, which enhances T cell functionality, and a third nucleotide sequence encoding a self-cleaving peptide, which is located between the first and second nucleotide sequences.

### Claim 42 (depends on 40)

The nucleic acid of claim 40, wherein the armor polypeptide is IL-2, IL-5, IL-15, a co-stimulatory ligand, an anti-PDL1 antibody, or a fusion polypeptide comprising the anti-PDL1 antibody; optionally wherein the anti-PDL1 antibody is a single chain variable fragment (scFv), which is fused to an IL-2 polypeptide.

### Claim 43 (depends on 40)

The nucleic acid of claim 40, wherein the nucleic acid is an expression vector, optionally a viral vector.

### Claim 44 (depends on 1)

A genetically engineered immune cell, which expresses the anti-TACI CAR and/or the anti-BCMA CAR of claim 1, and optionally further expresses an armor polypeptide, which enhances T cell functionality.

### Claim 45 (depends on 44)

The genetically engineered immune cell of claim 44, which is a T cell, an NK cell, or a macrophage, optionally wherein the immune cell is a T cell.

### Claim 46 (depends on 26)

A method for eliminating undesired cells in a subject, the method comprising administering to a subject in need thereof an effective amount of the genetically engineered immune cell of claim 26, or a pharmaceutical composition comprising such.

### Claim 47 (depends on 46)

The method of claim 46, wherein the undesired cells are cancer cells.

### Claim 48 (depends on 46)

The method of claim 46, wherein the subject is a human cancer patient.

### Claim 49 (depends on 48)

The method of claim 48, wherein the human cancer patient comprises BCMA+ and/or TACI+ cancer cells.

### Claim 50 (depends on 49)

The method of claim 49, wherein the cancer cells are multiple myeloma cells, lung cancer cells, gastric cancer cells, breast cancer cells, or testis cancer cells.
